NHEJ1抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: PC-3 cell lysate, Primary antibody: P05988(NHEJ1 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P05988(NHEJ1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P05988(NHEJ1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The NHEJ1 antibody is a crucial tool in studying the molecular mechanisms of DNA double-strand break (DSB) repair, particularly in the non-homologous end joining (NHEJ) pathway. NHEJ1 (Non-Homologous End Joining Factor 1), also known as XLF (XRCC4-like factor), is a core protein involved in the classical NHEJ (c-NHEJ) pathway, which is essential for maintaining genomic stability. It functions by interacting with XRCC4 to bridge DNA ends and facilitate ligation by DNA Ligase IV, particularly in repairing DSBs during V(D)J recombination in lymphocytes and general genome maintenance. Defects in NHEJ1 are linked to severe combined immunodeficiency (SCID), radiosensitivity, and increased cancer susceptibility.

The NHEJ1 antibody specifically detects the NHEJ1 protein in various experimental applications, including Western blotting, immunofluorescence, and immunoprecipitation. It is widely used in cancer research, immunology, and genetic studies to investigate DNA repair deficiencies, genomic instability, and immune system disorders. Researchers employ this antibody to assess NHEJ1 expression levels, localization, and interactions with other repair machinery components (e.g., Ku70/80. XRCC4) in both normal and disease models. Commercially available NHEJ1 antibodies are typically raised in rabbit or mouse hosts, with validation in knockout cell lines to confirm specificity. Its applications extend to clinical research, particularly in studying NHEJ1-related pathologies and evaluating therapeutic strategies targeting DNA repair pathways.